Welcome to our dedicated page for Lisata Therapeutics SEC filings (Ticker: LSTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Lisata Therapeutics, Inc. filings document material events, operating updates, and capital-structure matters for a clinical-stage pharmaceutical company focused on certepetide and related solid-tumor therapy development. Recent Form 8-K disclosures include financial results, Regulation FD materials, corporate presentations, material agreements, shareholder-voting matters, governance topics, and clinical or regulatory disclosures.
The filing record also documents changes to certepetide commercialization rights, including the termination of a Greater China license and collaboration agreement related to research, development, and commercialization of the product candidate. These disclosures frame Lisata’s formal reporting around program development, partnership economics, public-company governance, and transaction-related capital structure matters.
Lisata Therapeutics entered into a worldwide non-exclusive license agreement with Catalent, Inc. to allow Catalent to use Lisata's iRGD cyclic peptide, certepetide, as an antibody drug conjugate (ADC) payload on Catalent's SMARTag4 ADC platform. Catalent will assume full responsibility for research, development and commercialization costs, while Lisata is eligible for pre-determined development milestone payments of up to $10.5 million, tiered revenue sharing on future sales and/or partnerships, and a portion of any sublicense consideration. The agreement runs product-by-product and country-by-country until the end of the royalty term and may be terminated for material breach, bankruptcy/insolvency, or by Catalent on 30 days' notice. Catalent granted Lisata a right of first negotiation if Catalent initiates an organized out-licensing process for an asset arising from the collaboration. The company will file the full agreement as an exhibit to its Annual Report for the fiscal year ending December 31, 2025.
Lisata Therapeutics (Nasdaq:LSTA) filed an 8-K (Item 7.01 Regulation FD) announcing preliminary cohort B data from its Phase 2 ASCEND trial evaluating certepetide plus standard chemotherapy in metastatic pancreatic ductal adenocarcinoma. The company furnished a press release (Ex. 99.1) and investor slide deck (Ex. 99.2); the 8-K itself contains no numerical efficacy or safety results. Because the information is furnished, it is not deemed “filed” under the Exchange Act and carries no Section 18 liability. The disclosure is potentially material given certepetide’s status as the lead asset targeting a high-mortality cancer, yet the market impact depends on data contained only in the exhibits.